Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ikonisys Inc.

www.ikonisys.com

Latest From Ikonisys Inc.

Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q4 2007

Highlights from the Q4 2007 review of medical device and in vitro diagnostics/research dealmaking: there was a boost in medical device acquisitions--with patient monitoring in particular, which accounted for about half the total of this period--capping off an impressive year in medtech M&A activity. Of note in the in vitro diagnostics/research space was glucose monitoring, which brought in 60% of the total GM segment's $160 million in financing for the entire year.
BioPharmaceutical Medical Device

Overcoming Skepticism About Cancer Diagnostics

In cancer diagnostics skepticism and optimism exist side by side. This is evident from a growing dichotomy between the spurt of early research projects, fueled by new technologies and increased government spending, and the lack of investor interest. Despite a brutal financing market and past disappointments, a few start-ups determined to address the field's unmet needs are pursuing development of new markers and detection technologies and gaining momentum.
Medical Device Business Strategies

Start-Up Previews (10/01)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The Science of Senescence, features profiles of Centagenetix Inc., Elixir Pharmaceuticals Inc., Hormos Medical Corp. and Rejuvenon Corp. Plus these Selected Start-Ups across Health Care: Ceros Ltd., Corgentech Inc., CryoCor Inc. and Ikonisys Inc.

Ikonisys Inc.

Two-year-old Ikonisys has developed a cell-based analysis system for detecting rare cells in blood. Its first application is detection of fetal cells in maternal blood, a longstanding ambition of many companies, none of which has succeeded to date. The test would detect the most common birth defects earlier in a pregnancy and more accurately than existing methods. Ikonisys also sees a big opportunity in cancer for early detection of disease and micrometastasis.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ikonisys Inc.
  • Senior Management
  • Petros Tsipouras, CEO
    Louise A Mawhinney, SVP, CFO
    Paul White, Pres.
  • Contact Info
  • Ikonisys Inc.
    Phone: (203) 776-0791
    5 Science Park
    New Haven, CT 06511
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register